广东一力集团制药股份有限公司

Yili Pharmaceutical Co., Ltd. (formerly Guangdong Yili Group Pharmaceutical Co., Ltd.) is a high-tech pharmaceutical enterprise in China specializing in the research, development, manufacturing, and sales of traditional Chinese medicines (TCM) and chemical drugs. Founded in 2008 and headquartered in Sihui, Guangdong, the company operates multiple advanced manufacturing bases across Guangdong and Guangxi. Its product portfolio includes over 190 drug approvals, featuring its landmark Class 1.1 TCM innovative drug, Hu Zhen Qing Feng Jiao Nang (approved in 2021 for acute gouty arthritis), alongside widely used OTC products like Ke Te Ling. Yili Pharmaceutical is committed to green manufacturing, integrating TCM extraction with the production of organic fertilizers from herbal waste to create a circular economy.